FDA grants emergency licence for Lilly’s COVID-19 antibody combo
pharmaphorum
FEBRUARY 10, 2021
The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more severe symptoms that may need hospital treatment. There are a range of other antibody therapies in various stages of development.
Let's personalize your content